NCT00418236View on ClinicalTrials.gov

Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

CompletedOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

April 30, 2010

Conditions

Breast Cancer

Trial Locations (37)

1303

Sofia

1431

Sofia

2196

Johannesburg

3400

Cluj-Napoca

6600

Iasi, Jud. Iasi

7130

Somerset West

7500

Parow

10000

Zagreb

11800

Agarismo

23000

Zadar

30510

Krakow

50410

Tartu

55430

Brooklyn Center

57201

Watertown

58104

Fargo

58401

Jamestown

58503

Bismarck

59101

Billings

59715

Bozeman

70231

Bucharest

83642

Meridian

91786

Upland

92108

San Diego

Unknown

Buenos Aires

Santiago

Pretoria

18095-458

Sorocaba

74175-080

Goiânia

78008-400

Mato Grosso

V5Z 2N6

Vancouver

R3A 1M3

Winnipeg

G1V 3M7

Québec

J1H 4J6

Sherbrooke

DK-7100

Vejle

101 28

Tallinn

1081 HV

Amsterdam

02-341

Warsaw

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00418236 - Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density | Biotech Hunter | Biotech Hunter